$18.94
0.89% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
US8753722037
Symbol
TNDM

Tandem Diabetes Care, Inc. Stock price

$18.94
-2.54 11.83% 1M
-17.94 48.64% 6M
-17.08 47.42% YTD
-21.49 53.15% 1Y
-42.05 68.95% 3Y
-68.87 78.43% 5Y
-89.56 82.54% 10Y
-173.66 90.17% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.17 0.89%
ISIN
US8753722037
Symbol
TNDM
Sector

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$1.2b
Net debt
$-14.3m
Cash
$368.6m
Shares outstanding
66.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.28 | 1.23
EV/Sales
1.27 | 1.22
EV/FCF
negative
P/B
8.12
Financial Health
Equity Ratio
27.19%
Return on Equity
-36.50%
ROCE
-14.50%
ROIC
-24.79%
Debt/Equity
2.28
Financials (TTM | estimate)
Revenue
$983.0m | $1.0b
EBITDA
$-75.1m | $32.8m
EBIT
$-91.9m
Net Income
$-183.9m | $-95.6m
Free Cash Flow
$-50.2m
Growth (TTM | estimate)
Revenue
27.66% | 8.91%
EBITDA
42.55% | 139.75%
EBIT
37.47%
Net Income
-29.93% | 0.48%
Free Cash Flow
27.00%
Margin (TTM | estimate)
Gross
52.22%
EBITDA
-7.64% | 3.20%
EBIT
-9.35%
Net
-18.71% | -9.33%
Free Cash Flow
-5.11%
More
EPS
$-2.78
FCF per Share
$-0.75
Short interest
18.46%
Employees
2.65k
Rev per Employee
$350.00k
Show more

Is Tandem Diabetes Care, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Tandem Diabetes Care, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Tandem Diabetes Care, Inc. forecast:

16x Buy
55%
12x Hold
41%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Tandem Diabetes Care, Inc. forecast:

Buy
55%
Hold
41%
Sell
3%

Financial data from Tandem Diabetes Care, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
983 983
28% 28%
100%
- Direct Costs 470 470
20% 20%
48%
513 513
35% 35%
52%
- Selling and Administrative Expenses 405 405
15% 15%
41%
- Research and Development Expense 201 201
15% 15%
20%
-75 -75
43% 43%
-8%
- Depreciation and Amortization 17 17
3% 3%
2%
EBIT (Operating Income) EBIT -92 -92
37% 37%
-9%
Net Profit -184 -184
30% 30%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Tandem Diabetes Care, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tandem Diabetes Care, Inc. Stock News

Neutral
Business Wire
8 days ago
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access p...
Neutral
Business Wire
18 days ago
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott ...
Neutral
Business Wire
about 2 months ago
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00am Eastern Time (7:00am Pacific Time), Jefferies Global Healthcare Conference ...
More Tandem Diabetes Care, Inc. News

Company Profile

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Head office United States
CEO John Sheridan
Employees 2,650
Founded 2006
Website www.tandemdiabetes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today